« back to reports
Table of contents
Q3 2024
Pharmatech Report
December 13, 2024
Fill out the form to download a preview of this report. The full report is available through the PitchBook Platform.
Key DNA and cell-free innovations lift pharmatech upward
The pace of VC deals in the pharmatech sector picked up with 65 deals completed in Q3 compared with 47 in Q2, despite a dip to $1.1 billion invested in total.
The sector is propelled forward by technologies that work to enhance precision, scalability, and speed across pharmaceutical and biotech research, manufacturing, and development. Our latest Emerging Tech Research outlines DNA synthesis services and cell-free manufacturing as key innovation opportunities, with spotlights on VC-backed companies Elegen and Nuclera.
Table of contents
| Vertical update | 3 |
| Q3 2024 timeline | 5 |
| Pharmatech VC deal summary | 6 |
| Pharmatech landscape | 7 |
| Pharmatech VC ecosystem market map | 8 |
| Pharmatech PE ecosystem market map | 9 |
| VC and PE activity | 10 |
| Innovation spotlights | 22 |
| Cell-free manufacturing | 23 |
| DNA synthesis services | 25 |
| Select company highlights | 27 |
| Elegen | 28 |
| Nuclera | 31 |